Background: Between May 1995 and April 1996, 20 patients with Behçet’s disease were successfully treated with interferon α2a (IFN-α2a) 9 million IU/day three times a week and 16 patients with colchicine 1.5 mg/day orally for 3 months. Objective: To study the long-term effects of IFN treatment in Behçet’s disease. Methods: Between the years of 1996 and 1999, the patients were followed up every 3 months or whenever indicated. Retrospective evaluation was performed. Results: In 56% of the patients with complete remission or partial remission at the end of IFN-α2a treatment, long-term remissions ranging from 36 to 48 months were observed. Conclusion: IFN-α2a treatment is an effective treatment modality in Behçet’s disease with the advantage of inducing prolonged remissions.

Keywords:
Behçet’s disease, Interferon α
1.
Tsambaos D, Eichelberg D, Goos M: Behçet’s syndrome: Treatment with recombinant leukocyte alpha-interferon. Arch Dermatol Res 1986;278:335–336.
2.
Stadler R, Bratzke B, Baumann I: Morbus Behçet und exogenes Interferon: erfolgreicher Behandlungsversuch mit recombiniertem α-A-IFN. Hautarzt 1987;38:97–100.
3.
Kaneko F, Takahashi Y, Muramatsu R, Adachi K, Nakane A, Minagava T: Natural killer cell numbers and function in peripheral lymphoid cells in Behçet’s disease. Br J Dermatol 1985;113:313–318.
4.
Hamzaoui K, Ayed K, Slim A, Hamza M, Touraine J: Natural killer cell activity, interferon-gamma and antibodies to herpes viruses in patients with Behçet’s disease. Clin Exp Immunol 1990;79:28–34.
5.
Zouboulis CC, Treudler R, Orfanos CE: Morbus Adamantiades-Behçet: therapeutischer Einsatz von systemischem rekombinantem Interferon-alfa-2a. Hautarzt 1993;44:440–445.
6.
Dündar S, Özcebe Oİ, Özdemir O, Kirazlı Ş: Alpha interferon in the treatment of Behçet’s disease; in Godeau P, Wechsler B (eds): Behçet’s Disease. New York, Elsevier Scientific Publications, 1993, pp 665–670.
7.
Alpsoy E, Yılmaz E, Başaran E: Interferon therapy for Behçet’s disease. J Am Acad Dermatol 1994;31:617–619.
8.
Hamuryudan V, Moral F, Yurdakul S, Mat C, Tüzün Y, Özyazgan Y, Direskeneli H, Akoğlu T, Yazıcı H: Systemic interferon alpha 2b treatment in Behcet’s syndrome. J Rheumatol 1994;21:1098–1100.
9.
Azizlerli G, Sarıca R, Köse A, Övül C, Kavala M, Kayabalı M, Erkan F, Kural Z: Interferon alfa-2a in the treatment of Behçet’s disease. Dermatology 1996;192:239–241.
10.
Azizlerli G, Sarıca R, Köse A, Övül C, Singer R, Kural Z: The long-term treatment with interferon alfa-2a in Behçet’s disease; in Hamza M (ed): Behçet’s Disease. Tunis, Pub Adhoua; 1997, pp 453–457.
11.
Georgiou S, Monastırlı A, Pasmatzi E, Gartaganis S, Goerz G, Tsambaos D: Efficacy and safety of systemic recombinant interferon-alpha in Behçet’s disease. J Intern Med 1998;243:367–372.
12.
O’Duffy JD, Calamia K, Cohen S, Goronzy JJ, Herman D, Jorizzo J, Weyand C, Matteson E: Interferon-alpha treatment of Behçet’s disease. J Rheumatol 1998;25:1938–1944.
13.
Kötter I, Eckstein AK, Stübiger N, Zierhut M: Treatment of ocular symptoms of Behçet’s disease with interferon-α2a: A pilot study. Br J Ophthalmol 1998;82:488–494.
14.
Solak C, Gürler A: Interferon α2a treatment in patients with mucocutaneous Behçet’s disease. 6th Natl Congr Behçet’s Dis, Istanbul, November 1997.
15.
Zouboulis CC, Orfanos CE: Treatment of Adamantiades-Behçet disease with systemic interferon alfa. Arch Dermatol 1998;134:1010–1016.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.